Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00782288 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Digitoxin to Treat Cystic Fibrosis
A Phase 2 study, sponsored by National Jewish Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00782288 is a Phase 2 study that has completed, run by National Jewish Health. The registered enrollment target is 24 participants.
The verdict
NCT00782288, a Phase 2 study, has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will measure the inflammatory effects of digitoxin on IL-8 and neutrophil counts in induced sputum in stable Cystic Fibrosis (CF) patients and the pharmacokinetics of digitoxin in serum. Funding Source-FDA OOPD
Interventions
- OTHER placebo
- DRUG digitoxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-08 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00782288
The ClinicalTrials.gov registry entry for NCT00782288 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00782288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00782288 about?
NCT00782288 is a clinical study titled "Phase II Study of Digitoxin to Treat Cystic Fibrosis". This study will measure the inflammatory effects of digitoxin on IL-8 and neutrophil counts in induced sputum in stable Cystic Fibrosis (CF) patients and the pharmacokinetics of digitoxin in serum. Funding Source-FDA OOPD
What is the current status of trial NCT00782288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2010-08. Estimated completion is 2016-08.
What interventions are being tested in trial NCT00782288?
The interventions under investigation include: placebo (OTHER), digitoxin (DRUG).
Who is sponsoring clinical trial NCT00782288?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.